iSpecimen stock faces an October 9 vote on dilution

Published on 10/07/2026 at 04:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

iSpecimen stock was last at USD 1.05 on October 5, 2026, valuing the company at USD 2.7 million. A shareholder vote covers financing and an AI deal.

ISPC, US45032V3069, Illustration mit AI erstellt.

iSpecimen stock (ISIN US45032V3069) closed at USD 1.05 on Nasdaq on October 5, 2026, after falling 2.78 percent during the session. The immediate catalyst is a shareholder meeting scheduled for October 9, where investors will vote on financing powers, a potential reverse split and a USD 4.5 million AI asset acquisition.

October 9 vote sets the agenda

According to Stock Titan, the virtual meeting begins at 10:00 a.m. ET on October 9, 2026. The proxy covers five proposals, including approval for share issuance above the Nasdaq 19.99 percent threshold and authority for a reverse split between 1-for-10 and 1-for-100.

The proposed Foldlab AI asset acquisition carries USD 4.5 million of consideration, split between USD 2.0 million in cash and USD 2.5 million in iSpecimen stock, according to Stock Titan. The stock portion would remain in escrow for five years, keeping the transaction tied to future dilution and liquidity considerations.

Revenue pressure meets financing flexibility

iSpecimen's Q2 2026 revenue fell 83 percent and its net loss widened, according to Quartr. That comparison makes the October proposals more consequential because the company is seeking both strategic flexibility and additional funding capacity.

The future-financing proposal would permit convertible or equity-linked securities priced at a discount of up to 80 percent from the applicable lowest volume-weighted average price, while the May 2026 financing includes anti-dilution and most-favored-nation provisions. The proxy also lists 2,518,590 shares outstanding as of August 12, 2026, according to Stock Titan.

Nasdaq listing remains central

iSpecimen describes itself as an online marketplace connecting medical researchers with healthcare providers supplying human biospecimens, and identifies Nasdaq as its trading venue under ticker ISPC on its investor relations page. The proposed reverse split is designed to give the board flexibility to lift the per-share price if Nasdaq compliance requires it.

Stock remains near USD 1

On October 5, 2026, iSpecimen traded between USD 1.02 and USD 1.09, with volume of 124,801 shares and a market capitalization of USD 2.7 million. The Nasdaq quotation gives the October 9 vote a direct market consequence because the proposed financing and reverse-split powers could materially change the share count and per-share price.